1. Cotran, R. S., V. Kumar, andS. L. Robbins. 1989.Pathologic Basis of Diseases. Philadelphia, PA, W. B. Saunders, pp. 40?63.
2. Ulich, T. R., L. R.Watson, S.Yin, K.Guo, P.Wang, H.Thang, and J. delCastillo. The intratracheal administration of endotoxin and cytokines: I. Characterization of LPS-induced IL-1 and TNF mRNA expression and the LPS-, IL-1-, and TNF-induced inflammatory infiltrate.Am. J. Pathol. 138:1485?1496.
3. Ulich, T. R., S. Yin, D. G. Remick, D. Russel, S. P. Eisenberg, andT. Kohno. 1993. Intratracheal administration of endotoxin and cytokines: IV. The soluble tumor necrosis factor receptor type I inhibits acute inflammation.Am. J. Pathol.142:1335?1338.
4. Ulich, T. R., E. S. Yi, S. Yin, C. Smith, andD. G. Remick. 1994. Intratracheal administration of endotoxin and cytokines: VII. The soluble interleukin-1 receptor and the soluble tumor necrosis factor receptor II (p80) inhibit acute inflammation.Clin. Immunol. Immunopathol. 72:137?140.
5. Ulich, T. R., S. Yin, K. Guo, J. del Castillo, S. P. Eisenberg, andR. C. Thompson. 1991. The intratracheal administration of endotoxin and cytokines: III. The interleukin-1 (IL-1) receptor antagonist inhibits endotoxin- and IL-1-induced acute inflammation.Am. J. Pathol. 138:521?524.